
Prestige Consumer Healthcare Inc. PBH

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001295947

C/D

on the C/D boundary of 370 graded peers in healthcare

rank 216 of 370; percentile 58.3; sampling error 2.5 points; lower is stronger



C/D, the tortoise




Scoreboard	
Profitability	C percentile 51.3
Solvency	C percentile 46.8
Growth and financing	C percentile 54.3
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $3.5B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	12 of 14
Graded from	filings received through May 14, 2026 160 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$49.25 2026-10-20; market equity $2.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received May 14, 2026

- Major Brands" of this Annual Report on Form 10-K for information regarding market share. We compete for consumers' attention based on a number of factors, including brand recognition, product quality, performance, value to consumers, price and product availability at the retail level. Advertising, marketing, merchandising and packaging and the timing of new product introductions and line extensions also have a significant impact on consumer buying decisions and, as a result, on our market share and our sales. Our markets are highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 51.3						
Gross profitability	17.0%	32.3%		67.6	371	2026-03-31
Return on invested capital	8.2%	9.3%		52.1	74	2026-03-31
Accruals ratio	(2.0%)	(6.6%)		76.3	812	2026-03-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	0.8 pts	2.8 pts	9.1	242	2026-03-31
Solvency, sleeve percentile 46.8					
Twelve-month failure probability	not computable	0.06%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	4.04	(0.30)	21.7	757	2026-03-31
Net debt to EBITDA	2.73x	1.82x	67.6	75	2026-03-31
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2025-03-31; latest annual assets end 2026-03-31					
Current ratio	3.57x	2.96x	51.0	840	2026-03-31
Growth and financing, sleeve percentile 54.3					
Revenue growth, three-year compound	(1.2%)	10.1%	74.3	414	2026-03-31
Free cash flow growth, three-year compound	3.6%	10.9%	63.2	96	2026-03-31
Reinvestment rate	(22.4%)	37.1%	80.6	104	2026-03-31
Asset growth, three years	1.4%	2.1%	48.6	705	2026-03-31
Net share issuance, one year	(4.1%)	2.4%	4.7	633	2026-05-12

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
211	Cooper Companies, Inc. (COO)	56.9	C	
212	Aquestive Therapeutics, Inc. (AQST)	57.2	C	
213	Tango Therapeutics, Inc. (TNGX)	57.5	C	dilution
214	Rocket Pharmaceuticals, Inc. (RCKT)	57.7	C/D	degenerate inputs
215	Cryo Cell International Inc. (CCEL)	58.0	C/D	
216	Prestige Consumer Healthcare Inc. (PBH)	58.3	C/D	
217	Becton Dickinson & Co. (BDX)	58.5	C/D	
218	Option Care Health, Inc. (OPCH)	58.8	C/D	
219	electroCore, Inc. (ECOR)	59.1	C/D	
220	Cryoport, Inc. (CYRX)	59.3	C/D	late filer
221	Perspective Therapeutics, Inc. (CATX)	59.6	C/D	dilution, fortress balance sheet

What the price implies

at the 2026-10-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(17.0%)	8.0%	32
Distance from 52-week high	(29.7%)	(29.7%)	50
EBIT to enterprise value	9.5%	(1.5%)	91
Free cash flow yield	10.5%	(1.0%)	92
Book value to price	0.82	0.28	82
Sales to price	0.47	0.30	64
Composite equity issuance, five years	(5.2%)	20.5%	20
Relative strength against the sector, log excess return	(0.40)	(0.13)	32

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2026-03-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$89.1M
Operating cash flow, four quarters	$249.4M
Months of runway	not finite
Days since last periodic filing	76 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$25.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$595.6M	2026-03-31	2026-05-14	10-K	26-000016
2	assets	us-gaap:Assets	$3.5B	2026-03-31	2026-05-14	10-K	26-000016
3	operating income	us-gaap:OperatingIncomeLoss	$309.4M	2026-03-31	2026-05-14	10-K	26-000016
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$257.5M	2026-03-31	2026-05-14	10-K	26-000016
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$67.2M	2026-03-31	2026-05-14	10-K	26-000016
6	total debt	us-gaap:LongTermDebt	$994.0M	2026-03-31	2026-05-14	10-K	26-000016
7	book equity	us-gaap:StockholdersEquity	$1.9B	2026-03-31	2026-05-14	10-K	26-000016
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$63.9M	2026-03-31	2026-05-14	10-K	26-000016
9	total debt	us-gaap:LongTermDebt	$992.4M	2025-03-31	2026-05-14	10-K	26-000016
10	book equity	us-gaap:StockholdersEquity	$1.8B	2025-03-31	2026-05-14	10-K	26-000016
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$97.9M	2025-03-31	2026-05-14	10-K	26-000016
12	net income	us-gaap:NetIncomeLoss	$190.3M	2026-03-31	2026-05-14	10-K	26-000016
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$257.6M	2026-03-31	2026-05-14	10-K	26-000016
14	assets	us-gaap:Assets	$3.4B	2025-03-31	2026-05-14	10-K	26-000016
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2026-03-31	2026-05-14	10-K	26-000016
16	gross profit	us-gaap:GrossProfit	$634.5M	2025-03-31	2026-05-14	10-K	26-000016
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2025-03-31	2026-05-14	10-K	26-000016
18	gross profit	us-gaap:GrossProfit	$624.4M	2024-03-31	2026-05-14	10-K	26-000016
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2024-03-31	2026-05-14	10-K	26-000016
20	gross profit	us-gaap:GrossProfit	$625.3M	2023-03-31	2025-05-09	10-K	25-000017
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2023-03-31	2025-05-09	10-K	25-000017
22	gross profit	us-gaap:GrossProfit	$620.6M	2022-03-31	2024-05-15	10-K	24-000017
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2022-03-31	2024-05-15	10-K	24-000017
24	current assets	us-gaap:AssetsCurrent	$431.5M	2026-03-31	2026-05-14	10-K	26-000016
25	current liabilities	us-gaap:LiabilitiesCurrent	$120.9M	2026-03-31	2026-05-14	10-K	26-000016
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$1.7B	2026-03-31	2026-05-14	10-K	26-000016
27	liabilities	us-gaap:Liabilities	$1.6B	2026-03-31	2026-05-14	10-K	26-000016
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$31.3M	2026-03-31	2026-05-14	10-K	26-000016
29	operating income	us-gaap:OperatingIncomeLoss	$336.8M	2025-03-31	2026-05-14	10-K	26-000016
30	interest expense	us-gaap:InterestExpense	$1.8M	2025-03-31	2025-05-09	10-K	25-000017
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$11.2M	2026-03-31	2026-05-14	10-K	26-000016

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$251.5M	2025-03-31	2026-05-14	10-K	26-000016
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.2M	2025-03-31	2026-05-14	10-K	26-000016
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$248.9M	2024-03-31	2026-05-14	10-K	26-000016
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9.6M	2024-03-31	2026-05-14	10-K	26-000016
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$229.7M	2023-03-31	2025-05-09	10-K	25-000017
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.8M	2023-03-31	2025-05-09	10-K	25-000017
38	current assets	us-gaap:AssetsCurrent	$448.3M	2025-03-31	2026-05-14	10-K	26-000016
39	current liabilities	us-gaap:LiabilitiesCurrent	$106.6M	2025-03-31	2026-05-14	10-K	26-000016
40	assets	us-gaap:Assets	$3.3B	2024-03-31	2025-05-09	10-K	25-000017
41	assets	us-gaap:Assets	$3.4B	2023-03-31	2024-05-15	10-K	24-000017
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	47,372,166	2026-05-12	2026-05-14	10-K	26-000016
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,414,707	2025-05-01	2025-05-09	10-K	25-000017

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.